Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSCW) EBITDA (2020 - 2025)

Historic EBITDA for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to -$3.7 million.

  • Ensysce Biosciences' EBITDA fell 68024.32% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.0 million, marking a year-over-year decrease of 7490.88%. This contributed to the annual value of -$6.7 million for FY2024, which is 3720.83% up from last year.
  • Latest data reveals that Ensysce Biosciences reported EBITDA of -$3.7 million as of Q3 2025, which was down 68024.32% from -$1.8 million recorded in Q2 2025.
  • Ensysce Biosciences' EBITDA's 5-year high stood at $644746.0 during Q3 2024, with a 5-year trough of -$16.9 million in Q3 2021.
  • Its 5-year average for EBITDA is -$3.6 million, with a median of -$2.6 million in 2023.
  • As far as peak fluctuations go, Ensysce Biosciences' EBITDA crashed by 407190.7% in 2021, and later surged by 12381.5% in 2024.
  • Ensysce Biosciences' EBITDA (Quarter) stood at -$2.0 million in 2021, then crashed by 209.0% to -$6.2 million in 2022, then surged by 49.11% to -$3.2 million in 2023, then decreased by 13.33% to -$3.6 million in 2024, then decreased by 4.6% to -$3.7 million in 2025.
  • Its EBITDA was -$3.7 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$2.0 million in Q1 2025.